Cite
Cramer SL, Miller AL, Pressey JG, et al. Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study. Front Oncol. 2018;7:327doi: 10.3389/fonc.2017.00327.
Cramer, S. L., Miller, A. L., Pressey, J. G., Gamblin, T. L., Beierle, E. A., Kulbersh, B. D., Garcia, P. L., Council, L. N., Radhakrishnan, R., Hendrix, S. V., Kelly, D. R., Watts, R. G., & Yoon, K. J. (2017). Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study. Frontiers in oncology, 7327. https://doi.org/10.3389/fonc.2017.00327
Cramer, Stuart L, et al. "Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study." Frontiers in oncology vol. 7 (2017): 327. doi: https://doi.org/10.3389/fonc.2017.00327
Cramer SL, Miller AL, Pressey JG, Gamblin TL, Beierle EA, Kulbersh BD, Garcia PL, Council LN, Radhakrishnan R, Hendrix SV, Kelly DR, Watts RG, Yoon KJ. Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study. Front Oncol. 2018 Jan 11;7:327. doi: 10.3389/fonc.2017.00327. eCollection 2017. PMID: 29376028; PMCID: PMC5768639.
Copy
Download .nbib
